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Abstract
Atypical antipsychotic agents, such as clozapine, are used for treating psychosis and depression and have recently
been found to modulate neuroinflammation. We have shown previously that treatment of mice with the atypical
antipsychotic agents, clozapine or risperidone, attenuates disease severity in experimental autoimmune encephalomyelitis
(EAE); however, the mechanism by which they are protective is unknown. In this study, we investigated the effects of
clozapine on CD4+ T cell responses and found that clozapine did not significantly affect the expansion of myelin-specific
T cells, their differentiation into pathogenic subsets, or their encephalitogenic capacity to induce EAE. Interestingly,
although clozapine enhanced differentiation of regulatory T (Treg) cells, in vivo neutralization of Tregs indicated that Tregs
were not responsible for the protective effects of clozapine during the induction and effector phase of EAE. Taken
together, our studies indicate that clozapine does not mediate its protective effects by directly altering CD4 T cells.
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Introduction
Multiple sclerosis (MS) is a debilitating disease of the
central nervous system (CNS) that is mediated by in-
flammatory demyelination of the myelin sheaths that
surround neuronal axons [1]. Immune-mediated demye-
lination impairs nerve conduction and causes the clinical
symptoms of MS, which are diverse and include loss of
coordination, visual disturbances, fatigue, and paralysis;
the degree of which is assessed using the Expanded Dis-
ability Status Scale [2]. Although there are now a num-
ber of therapeutic options for relapsing-remitting MS
patients, they are not similarly effective in all patients
and only one has shown potential in the primary progres-
sive forms of MS. This is not surprising given that blood-
brain barrier (BBB) disruption is minimal in the progres-
sive forms [3] and current therapeutic strategies are
protein - based such as glatiramer acetate, interferon-β,
and natalizumab, which have limited capacity to cross the
intact BBB [4]. In addition, while ocrelizumab has shown
limited potential in the treatment of primary progressive
MS [5], its efficacy in patients may partly be determined
by the severity of BBB disruption. Therefore, effective
therapeutic options are urgently needed.
MS is considered a neuroinflammatory disease and
shares some pathophysiological similarities with several
neuropsychiatric disorders. For example, it is becoming
increasingly evident that neuropsychiatric disorders such
as schizophrenia and major depressive disorders are as-
sociated with inflammation in the CNS and character-
ized by chronic microglial activation [6]. These diseases
are associated with elevated inflammatory markers and,
in particular, the expression of inflammatory cytokines
interleukin (IL-) 1β, IL-6, and tumor necrosis factor-α,
which were found in post-mortem samples from suicide
victims with major depression [7] and schizophrenia [8].
Clinical treatments for psychiatric disease like fluoxetine,
risperidone, quetiapine, and clozapine have recently been
acknowledged for their immunomodulatory effects in
various models of inflammation [9–12] and show
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promise as immune-modulating agents. Abnormal serum
cytokine levels in schizophrenic patients are normalized
by treatment with atypical antipsychotics in some studies
[13], suggesting an immune - altering effect.
Recently, we have shown that the atypical anti-
psychotic agents risperidone and clozapine are effective
at reducing disease in experimental autoimmune en-
cephalomyelitis (EAE) [10], demonstrating that atypical
antipsychotic agents are potential treatments for MS.
While these agents show promise as therapeutics in MS
and other neuroinflammatory disorders, the mechanism
by which they reduce disease and alter inflammation is
not completely understood. Given that EAE is a disease
that is driven by autoreactive Th1 and Th17 cells and
that defective development of these subsets greatly alters
the susceptibility of mice to EAE, this study aimed to in-
vestigate if clozapine were able to reduce disease by
impairing CD4 T cell-mediated induction of EAE.
Materials and methods
Mice
All mice used were female and aged between 8 and
12 weeks. C57BL6/J were purchased from the Biomed-
ical Research Unit of the Malaghan Institute of Medical
Research (Wellington, NZ) and housed in the Victoria
University of Wellington animal facility. 2D2 TCRMOG35-
55 (CD45.2) mice expressing the T cell receptor (TCR)
specific for myelin oligodendrocyte glycoprotein (MOG)
35-55 and B6-SJptprca (CD45.1) mice were bred at the
Victoria University of Wellington animal facility. Food
and water were available ad libitum.
Induction of EAE and clozapine treatment
Active EAE
EAE was induced by subcutaneous (s.c) immunization in
the rear flanks of mice with MOG35-55 (50 μg/mouse;
Genscript, Piscataway, NJ, USA) emulsified in complete
Freund’s adjuvant (500 μg/mouse Mycobacterium tuber-
culosis) followed by intraperitoneal (i.p) injection of
200 ng/mouse pertussis toxin on days 0 and 2. Mice
were weighed and scored daily for signs of disease by a
non-blinded investigator, using the following disease rat-
ing scale: 0, normal; 1, partial tail paralysis; 2, full tail
paralysis; 3, full paralysis of one hind limb; 4, full paraly-
sis of both hind limbs; and 5, moribund. Clozapine was
kindly supplied by Douglas Pharmaceuticals Ltd.
(Auckland, New Zealand) and added to drinking water
1 day prior to EAE induction at a concentration cal-
culated to achieve a daily dose of 60 mg/kg. For regu-
latory T (Treg) neutralization, mice were injected
with 200 μg of anti-CD25 monoclonal antibody
(PC61; BioXCell, West Lebanon, NH, USA) or rat
IgG (Sigma-Aldrich, St. Louis, MO, USA) i.p 3 days
prior to EAE induction and maintained with repeat
injections at 7 and 14 days post immunization (d.p.i).
Adoptively transferred EAE
Donor C57BL6/J mice were immunized for EAE as de-
scribed above but without the pertussis toxin. Spleens
and draining lymph nodes were harvested at 12 d.p.i,
and single-cell suspensions were made by passage
through a 70-μm cell strainer (BD Biosciences, Franklin
Lakes, NJ). Red blood cells were lysed using Red Blood
Cell Lysis Buffer Hybri-Max (Sigma-Aldrich, St. Louis,
MO). Splenocytes were washed and re-suspended in cul-
ture medium containing Dulbecco’s modified Eagle
medium (DMEM), 100 U/mL penicillin, 100 μg/mL
streptomycin, 10 mM HEPES, 2 mM L-glutamine,
50 μM 2-mercaptoethanol, non-essential amino acids
and 10% fetal calf serum (all from Life Technologies,
Carlsbad, CA, USA). Donor cells were cultured in tissue
culture flasks at 1 × 107 cells/mL with IL-12p70 (20 ng/
mL; Peprotech, Rocky Hill, NJ, USA), XMG1.2 (10 μg/
mL; BioXCell, USA), MOG35-55 (50 μg/mL), and either
vehicle or clozapine (20 μM) at 37 °C and 5% CO2. After
96 h of stimulation, non-adherent donor cells were har-
vested and injected into recipient naïve C57BL/6J mice
(2 × 107 cells/mouse) followed by pertussis toxin
(200 ng/mouse) on days 0 and 2. Mice were monitored
daily for disease as described above.
In vivo proliferation assay
Splenocytes and lymph node cells were isolated from
2D2 TCRMOG35-55 mice as described and labelled with
CellTrace CFSE Cell Proliferation Kit (Life Technolo-
gies) according to the manufacturer’s protocol. CFSE-
labelled 2D2 TCRMOG35-55 cells (2 × 107) were injected
i.p into B6-SJptprca 1 day prior to EAE induction. At day
0, mice were immunized to induce EAE and euthanized
5 days post immunization. Proliferation of CD45.2+CD4+
cells were assessed in peripheral blood (cardiac puncture),
draining lymph nodes (inguinal and mesenteric), and
spleen by flow cytometry.
In vitro assays
Splenocytes, isolated as described above, were seeded in
flat bottom 96-well plates (BD Biosciences) at 1 × 106
cells/well. Splenocytes were stimulated with MOG35-55
(50 μg/mL) (Genscript) for 72 h before supernatant was
collected for cytokine detection.
T cell differentiation
Splenocytes were plated at 1 × 106 cells/well in flat bot-
tom 96-well plates (BD Biosciences). Th1 cells were in-
duced by addition of IL-12p70 (20 ng/mL) and 11B11
(10 μg/mL; a gift from the Malaghan Institute of Medical
Research). Th17 cells were induced by addition of
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transforming growth factor (TGF-) β1 (5 ng/mL;
eBioscience, San Diego, CA), IL-6 (20 ng/mL; BD Biosci-
ences), and XMG1.2 (10 μg/mL; BioXCell). Tregs were
induced by addition of TGF-β1 (5 ng/mL), MP5-20F3
(10 μg/mL), XMG1.2 (10 μg/mL), and 11B11 (10 μg/
mL). Clozapine or vehicle (AcOH) was added at indi-
cated final concentrations. Cells were incubated for 72 h
at 37 °C and 5% CO2 after which supernatant was col-
lected and T cells were stimulated with 50 ng/mL phorbol
12-myristate 13-acetate (PMA), 500 ng/mL ionomycin
(Sigma-Aldrich) and Golgi Stop (BD Biosciences) used ac-
cording to the manufacturer’s recommendations for a fur-
ther 5 h before analysis of T cell subsets by intracellular
flow cytometry.
Flow cytometry
For the detection of immune cells, cytokines, and tran-
scription factors, the following antibodies were used:
CD4 (GK1.5; Biolegend, San Diego, CA, USA), CD45
(30-F11; Biolegend), CD25 (PC61; Biolegend), CD8 (53-
6.7; Biolegend), CD11b (M1/70; Biolegend), CD3 (17A2;
Biolegend), IFN-γ (XMG1.2; BD Biosciences), T-bet (04-
46; BD Biosciences), RORγT (Q31-378; BD Biosciences),
IL-17A (TC11-18H10; BD Biosciences), Foxp3 (150D;
Biolegend), CD45.1 (A20; BD Biosciences), CD45.2 (104;
BD Biosciences), goat antirabbit FITC (BD Biosciences),
and rabbit antimouse dopamine D1 and D2 receptor
(both from Merck, Darmstadt, Germany). For cell sur-
face staining, cells were incubated with Fc Block (2.4G2;
BD Biosciences) for 15 min prior to staining with fluo-
rescently labelled antibodies for 20 min on ice. For intra-
cellular staining, cells were fixed, permeabilized, and
stained using Transcription Factor Buffer Set (BD Biosci-
ences) according to the manufacturer’s protocol. Flow
cytometry was performed on a BD FACS Canto II (BD
Biosciences) and analyzed using Flowjo software
(Treestar Inc., Ashland, OR, USA).
Cytokine measurement
Cytokines in the supernatant were measured by LEGEN-
Dplex Mouse Inflammation Panel multi-analyte flow assay
kit (Biolegend) or sandwich ELISA (BD Biosciences) ac-
cording to the manufacturer’s recommendations.
Statistics
Data were graphed and analyzed by one-way ANOVA,
two-way ANOVA, Student’s t test, and Mann-Whitney
test as indicated in each figure using GraphPad Prism
software (GraphPad, La Jolla, CA, USA). Dunnett’s and
Sidak’s post hoc multiple comparison test was performed
to determine significant differences between test groups.
P values of <0.05 were considered significant.
Results
Clozapine treatment delayed onset and reduced severity
of EAE
It has recently been shown that atypical antipsychotics
such as risperidone, clozapine, and quetiapine are able
to modulate the immune response and reduce disease
effectively during EAE [10, 11]; however, the mechanism
by which they mediate this effect is not yet fully under-
stood. To better understand this mechanism, we used a
dose of 60 mg/kg/day clozapine starting the day before
immunization to effectively reduce the disease course of
EAE (Fig. 1a), and this dose has also been shown re-
cently to work therapeutically when administered at 12
or 20 days post immunization (d.p.i) [14]. Consistent
with previous findings, vehicle-treated mice developed
clinical symptoms of EAE with a mean onset of disease
at 11 d.p.i whereas clozapine-treated mice experienced a
delayed disease onset with a mean of 16 d.p.i (Fig. 1b).
Mice that received clozapine had reduced peak disease
score (Fig. 1c), and this contributed to an overall reduc-
tion in disease burden (Fig. 1d). These results demon-
strate that clozapine is effective at reducing and delaying
EAE disease.
Treatment with clozapine did not alter MOG-specific T cell
expansion upon EAE induction
CNS inflammation and demyelination in MS and EAE
is dependent on the function of CD4+ T cells [15].
EAE is induced by immunization with a myelin self-
peptide such as MOG35-55, which causes a rapid ex-
pansion of antigen-specific CD4+ T cells that initiate
inflammation in the CNS [15]. Given the requirement
for CD4 T cell expansion, defects in T cell prolifera-
tion can reduce the severity of EAE [16, 17], and in
contrast, failure to suppress proliferation exacerbates
EAE as seen in IFN-γ [18] or Treg-deficient mice
[17]. A previous study reported that the atypical anti-
psychotic agent, quetiapine, reduced disease in EAE
by impairing CD4 T cell proliferation [11]. Given that
CD4 T cells express dopaminergic receptors (data
shown in Additional file 1) as well as other neuro-
transmitter receptors targeted by atypical anti-
psychotic agents [19, 20], we investigated whether
clozapine had affected MOG35-55-specific T cell ex-
pansion. To address this, we used an established in
vivo model of proliferation [16]. We show that
clozapine-treated mice maintained robust CD4+ T cell
expansion as assessed by the percentage of cells that
proliferated and the proliferative index in the periph-
eral blood (Fig. 2b), spleen (Fig. 2c), and draining
lymph nodes (Fig. 2d) indicating that orally adminis-
tered clozapine does not affect MOG-specific CD4+
expansion in vivo.
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Clozapine did not alter pathogenic T cell subsets but
promoted Tregs
EAE is a disease that is driven by pathogenic Th1 cells
expressing T-bet and IFN-γ as well as Th17 cells ex-
pressing RORγT and IL-17A. This dependence was dem-
onstrated when it was shown that mice which have
defective Th1 and Th17 development (i.e., IL-12p40-
deficient mice) were resistant to EAE [21]. In addition,
severity of EAE is regulated by Foxp3-expressing regula-
tory T cells (Tregs) that have immunosuppressive cap-
acity [22]. Clozapine has previously been shown to
decrease production of IFN-γ and enhance IL-4 and IL-
10 in poly (I:C)-stimulated PBMC cultures from schizo-
phrenia patients, which suggests an effect on CD4+ T
cell differentiation [23]. To assess development of Th1,
Th17, and Treg cell subsets during EAE, we measured
RORγT, T-bet, and Foxp3 expression in peripheral CD4+
T cells during EAE as these transcription factors are
master regulators of Th1 [24], Th17 [25], and Treg [26]
cells, respectively.
At 5 d.p.i, mice with EAE had a lower proportion of
Tregs (CD25+ FoxP3+) in the spleen than unimmunized
mice while mice with EAE had an increased proportion
of Th17 (RORγT+) when compared to unimmunized
mice. No difference in Tregs or Th17 cells was measured
between vehicle and clozapine-treated mice independent
of EAE (Fig. 3a). In contrast to the induction phase of
EAE, in the effector phase (i.e., 15 d.p.i), we observed a
subtle but significant increase in Tregs while the signifi-
cant increase in Th17 cells induced by EAE persisted.
Clozapine treatment had no effect on Tregs or Th17
cells in immunized or unimmunized mice (Fig. 3b).
T-bet expression was not detected by flow cytometry,
and instead, we used intracellular cytokine staining for
IFN-γ and IL-17A to identify Th1 and Th17 cells, re-
spectively (Fig. 3c), and found that IFN-γ+ and IL-17A+
CD4 T cells were unaffected by clozapine treatment
(Fig. 3d). These results were verified when no difference
in MOG35-55-specific IFN-γ and IL-17A recall responses
was detected between vehicle and clozapine-treated ani-
mals at 5 d.p.i (Fig. 3e) and 15 d.p.i (Fig. 3f ). It is worth
noting that we have previously found IL-17A in the
supernatant to be decreased after MOG35-55-specific re-
call response in risperidone-treated mice [10], suggesting
that clozapine may have a distinct mechanism of action
to that of risperidone.
To understand the effect of clozapine on the differ-
entiation of T cells, we stimulated splenocytes from
Fig. 1 Clozapine delayed the onset and reduced disease severity of EAE but did not alter antigen-specific T cell expansion. Mice were treated
with clozapine or vehicle 1 day prior to EAE induction and scored daily (0: normal to 5: moribund). a Disease course of mice. b Disease onset. c
Peak disease score. d Disease burden assessed by area under the curve analysis. Shown are the means and SEM of individual mice from two experi-
ments combined (n = 10 mice/group). ****p < 0.0001 by Mann-Whitney test
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2D2 TCRMOG35-55 mice with MOG35-55 peptide under
conditions to induce Th1 (Fig. 4a), Th17 (Fig. 4b),
and induced Tregs (iTregs) (Fig. 4c). When we added
clozapine into the culture medium, we did not detect
a significant difference in the induction of Th1 or
Th17 cells measured by IFN-γ+ (Fig. 4d) or IL-17A+
(Fig. 4e) CD4 T cells. We did however measure a
subtle but statistically significant decrease in T-bet+
(Fig. 4f ) and RORγT+ (Fig. 4g) T cells in the presence
of clozapine. Interestingly, we measured a significant
increase in Foxp3 protein expression in iTregs
(Fig. 4h) indicating that clozapine promotes Foxp3 ex-
pression. Additionally, the proportion of iTregs sig-
nificantly increased from 32.7% of CD4+ to 49.8%
(Fig. 4i) in the presence of clozapine; altogether, these
results indicate that clozapine promotes the gener-
ation of iTregs and Foxp3 expression. Despite min-
imal difference in Th1 or Th17 cell differentiation, we
measured significantly less IFN-γ (Fig. 4j) and IL-10
(Fig. 4k) in the supernatant after stimulating with
MOG35-55 peptide alone, suggesting a possible alter-
ation in downstream effector functions.
Protection from EAE by clozapine was not dependent on
regulatory CD4+ T cells
Our results indicate that in vitro, clozapine enhances the
development of CD25+ Foxp3+ Tregs. Tregs are known
to limit inflammatory damage during EAE, and their im-
portance was highlighted by the depletion of CD25+ or
Foxp3+ T cells during EAE, which resulted in exacer-
bated disease [27, 28]. Since Tregs are protective in this
model, we questioned whether promotion of Treg differ-
entiation by clozapine was responsible for its protective
effect during EAE. We neutralized Treg cells in vivo
prior to EAE induction by administration of anti-CD25
antibody. This treatment was maintained throughout the
experiment and effectively blocked CD25 (data shown in
Additional file 2). We found that neutralization of Tregs
exacerbated disease in untreated mice (Fig. 5a) whereas
clozapine-treated mice remained protected from disease
and sustained a lower overall disease burden (Fig. 5b)
and maintained a delayed onset of disease (Fig. 5c) and
peak disease score (Fig. 5d) paralleling mice which did
not receive anti-CD25. This data demonstrates that Treg
function is dispensable for protection by clozapine.
Fig. 2 Clozapine did not alter Th cell subsets in the periphery. a–d In vivo proliferation. Gating strategy to identify adoptively transferred 2D2
MOG35-55 TCR CD4 cells (a). Proliferation assessed by % proliferated and proliferation index in b blood, c spleen, and d draining lymph nodes.
p > 0.05 by Student’s t test. Shown is one representative experiment of two (n = 3 mice in each group)
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Clozapine did not alter encephalitogenicity of MOG35-55-
specific CD4+ T cells
Our in vitro model of T cell differentiation indicates that
clozapine does not alter the differentiation of CD4 T
cells into Th1 and Th17 cell subsets. However, these re-
sults show some potential for clozapine to alter T cell ef-
fector functions given that we measured less IFN-γ and
IL-10 in the supernatant when stimulated with MOG.
While our study has shown that Tregs do not mediate
protection in clozapine-treated mice, it is possible that
clozapine could be affecting the encephalitogenic cap-
acity of CD4+ T cells. We induced passive EAE by inject-
ing MOG35-55-specific T cells expanded in vitro in the
presence of clozapine into naïve mice. Adoptive transfer
of encephalitogenic T cells induced EAE with a similar
disease progression (Fig. 6a) and disease burden (Fig. 6b)
independent of whether clozapine was present during in
vitro expansion indicating that clozapine does not affect
the encephalitogenic capacity of CD4 T cells.
Discussion
Atypical antipsychotics like clozapine readily cross the
BBB and are used for treating psychiatric diseases like
schizophrenia. Recently, these medicines have been rec-
ognized as immune-modulating agents as they are able
to suppress inflammation associated with schizophrenia
[29]. Few studies are available describing the effects of
clozapine treatment on the immune response, but these
have shown that clozapine can inhibit the activation of
immune cells like microglia and T cells in response to
Fig. 3 Clozapine did not alter Th cell subsets in the periphery. Tregs and Th17 cells were analyzed by flow cytometry 5 d.p.i (a) and 15 d.p.i
(b; gating strategy shown in Additional file 3). Shown are the means and SEM of individual mice from one experiment with 5/group (a) or 2–3
experiments combined with 10–15 mice/group (b). c Representative dot plots of intracellular cytokine staining from spleen 15 d.p.i. d Graph of
IFN-γ+ and IL-17A+ cells presented as percentage of CD4. Shown are means and SEM of individual mice from one experiment (n = 5 mice/group).
e Splenocytes were re-stimulated with MOG peptide at 5 d.p.i for 72 h and IFN-γ and IL-17A in the supernatant measured by ELISA. Shown are
means and SEM of individual mice from one experiment. Shown are the means and SEM of individual mice from one experiment (n = 5 mice/
group). f Splenocytes were re-stimulated with MOG peptide 15 d.p.i for 72 h. IFN-γ and IL-17A in the supernatant measured by ELISA. Shown are
the means and SEM of individual mice from an experiment representative of four (n = 5 mice/group). Statistical analyses were performed using
two-way ANOVA and Sidak’s multiple comparison test
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inflammatory stimuli [12, 30, 31]. Given that both
schizophrenia and multiple sclerosis are inflammatory
diseases of the central nervous system and that cloza-
pine is able to reduce inflammation in the CNS, we
wished to investigate whether clozapine could be re-
purposed to treat progressive forms of multiple sclerosis
for which there is only one effective therapeutic option
available [5]. Indeed, we have shown that clozapine is
able to reduce disease in EAE, indicating that it is a great
candidate for multiple sclerosis; however, the precise
mechanism is not yet known. In this study, we show that
clozapine treatment does not significantly alter the de-
velopment of robust antigen-specific T cell responses
despite effective suppression of EAE disease.
The effect of clozapine on T cell activation has previ-
ously been investigated in human PBMCs and is
consistent with our findings, showing that clozapine in-
hibits secretion of IFN-γ after stimulation of CD3 and
CD28 [31]. In our study, we showed that clozapine in-
hibits IFN-γ secretion in response to an antigen; how-
ever, in contrast to the previous study, we did not
observe significant alterations in T cell differentiation to
Th1 or Th17 in vitro or during EAE.
One of the most striking findings in this study is that
clozapine promotes in vitro differentiation of Tregs and
expression of Foxp3, a key transcription factor for the
development and function of Tregs. Although clozapine
had the potential to augment Treg function, it did not
appear to be important for disease protection during
EAE as neutralization of CD25+ Tregs had no effect on
disease protection. Interestingly, while clozapine pro-
moted Treg differentiation, little effect was observed
Fig. 4 Clozapine promoted Treg expansion in an in vitro model of T cell differentiation. 2D2 TCRMOG35-55 splenocytes were cultured at 1 × 106
cells/well in Th differentiation medium and stimulated with MOG35-55 peptide for 72 h. Representative dot plots of (a) T-bet and IFN-γ in Th1
differentiating medium, b RORγT and IL-17A in Th17 differentiating medium, and c CD25 and Foxp3 in Treg differentiating medium gated
on CD4+ T cells after 72 h of stimulation with MOG35-55 with clozapine (20 μM) or vehicle. Graphical presentation of IFN-γ+ (d), IL-17A+
(f), or CD25+ Foxp3+ (h) T cells. Graphical representation of T-bet+ (e) and RORγT+ (g) as percentage of CD4. Foxp3 expression presented
as geometric MFI in all CD4 T cells after differentiating to Tregs (i). IFN-γ (j) and IL-10 (k) in the supernatant from splenocytes stimulated
with MOG35-55 peptide for 72 h. ****p < 0.0001 as assessed by one-way ANOVA with Dunnett’s multiple comparison test. **p < 0.01, ****p < 0.0001 by
Mann-Whitney test. Shown is a representative experiment of 4
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during differentiation to Th1 and Th17 cells. This obser-
vation could be explained by clozapine activating the
Akt pathway as has reported in various tissues [32–34],
and since this pathway is important for CD3, CD28 and
cytokine signalling [35]. Akt is upstream of the
mammalian target of rapamycin (mTOR) and regulates
T cell differentiation during activation. For example, sup-
pression of mTOR activity promotes the generation of
Foxp3+ Tregs [36], and the deletion of mTOR in CD4 T
cells enhances differentiation of Tregs but not Th1, Th2,
Fig. 5 Clozapine was protective independent of regulatory T cells. a–f Tregs were neutralized in mice 3 days before EAE induction and
maintained throughout the experiment. Clozapine was added to drinking water 1 day before induction for EAE and mice scored daily for disease
(0: normal to 5: moribund). Disease score of mice (a). Disease burden assessed by area under the curve analysis (b). Onset of clinical disease (c).
Peak disease score reached of mice with disease (d). Shown are the means and SEM of individual mice from two experiments combined (a–d n
= 5 mice/group). *p < 0.05, **p < 0.01 by two-way ANOVA and Sidak’s multiple comparison test. ••p < 0.01 by Mann-Whitney test. e–f IFN-γ (e) and
IL-17A (f) in the supernatant after MOG35-55-peptide-specific recall for 72 h. Shown are means and SEM of individual mice from one experiment
(n = 5 mice in each group)
Fig. 6 Clozapine did not alter encephalitogenic capacity of T cells to induce EAE. Passive EAE was induced in mice by injection of MOG-specific
cells expanded either in vehicle or clozapine. Disease score of mice (a). Disease burden of mice assessed by area under the curve (b). Shown are
the means and SEM of individual mice from three experiments combined (n = 15 mice/group). Mann-Whitney test was used to determine whether
disease burden (i.e., AUC) was statistically different between groups
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or Th17 cells [37], indicating a potential role for mTOR
in the mechanism of action of clozapine.
Despite the effects of clozapine in an in vitro differen-
tiation model, we did not find that these alterations were
important for disease protection during EAE as no dif-
ference in Th1, Th17, or Treg differentiation was de-
tected with treatment during the induction and effector
phase of disease even though mice were protected from
disease. This suggests that protection may not be medi-
ated through alteration of the T cell response directly. It
is possible that clozapine alters the ability of macro-
phages and microglia to become activated and initiate
disease in the CNS independent of CD4 T cells, although
this is yet to be shown. However, clozapine has recently
been shown to alter the production of inflammatory
cytokines from in vitro cultured microglia [30], and we
have shown previously that clozapine suppresses the
production of IL-12 in bone marrow-derived macro-
phages stimulated with lipopolysaccharide indicating
that clozapine is able to alter macrophage activation
[10]. This effect may be important given that once auto-
reactive T cells initiate the inflammatory response in the
CNS, inflammatory monocytes are recruited and their
numbers correlate to severity of disease [38]. The ability
of clozapine to alter macrophage activation to be less in-
flammatory may contribute to attenuated disease during
treatment as these cells are predominant in the demye-
linating regions of the brain in EAE and MS [39].
In conclusion, while clozapine is effective at reducing
EAE in mice, we did not find defective antigen-specific
T cell responses. Given that we have recently shown clo-
zapine to inhibit the activation of microglia in the CNS
during EAE [14] and that clozapine alters the activation
of LPS-stimulated macrophages directly [10], instead, we
believe the mechanism of protection may involve other
immune pathways including the alteration of myeloid
activation in the CNS specifically. We have recently
shown that clozapine effectively reduces established EAE
disease when given therapeutically at 12 or 20 d.p.i, indi-
cating that clozapine has potential as a therapy for MS
[14]. Finally, it has been suggested that prospective ther-
apies for progressive MS have immune-modulating
properties that target myeloid cell activation in the CNS
and readily cross an intact BBB [40], further supporting
the feasibility of using clozapine as a potential therapy
for progressive MS.
Additional files
Additional file 1: Gating strategy for identifying dopaminergic and
adrenergic receptors on T cells. Spleens were isolated from mice 15 d.p.i
and analyzed by flow cytometry for dopamine and adrenergic receptor
expression. A gating strategy for identifying CD4 (bottom left), CD8
(bottom center), and Tregs (bottom right). Representative histograms for
expression of B dopamine D1 receptor (D1R) and C dopamine D2 receptor
(D2R) on CD4 T cells. Graphical representation of receptor expression on
different T cell subsets of D D1R and E D2R. Shown are means and SEM of
individual mice from one experiment (n = 5 mice in each group). Statistical
analyses between healthy control and EAE mice conducted by two-way
ANOVA. (TIF 17402 kb)
Additional file 2: CD25 neutralization 0, 10, and 17 d.p.i Mice were
injected with 200 μg/mouse anti-CD25 (PC61) antibody at −3, 7, and 14
d.p.i CD25 neutralization was assessed by flow cytometry using Alexa
Fluor 488 conjugated anti CD25 (PC61) at days A 0, B 10, and C 17. CD4+
T cells were identified using the gating strategy described in Additional file 3.
(TIF 12283 kb)
Additional file 3: Gating strategy to identify CD4+ T cells and 2D2
MOG35-55 TCR CD4+. Single cells were gated using FSC-A and FSC-H.
Cells of interest were gated using FSC-A and SSC-A. Lymphocytes were
identified by CD11b− and CD3+ expression. CD4 T cells were distinguished
using CD8− and CD4+ expression. Tregs were identified as CD25+ and
Foxp3+. Th17 cells were identified as RORγT+. (TIF 14847 kb)
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BBB: Blood-brain barrier; CNS: Central nervous system; d.p.i: Days post
immunization; EAE: Experimental autoimmune encephalomyelitis;
i.p: Intraperitoneal; IL: Interleukin; iTreg: Induced Treg; MOG: Myelin
oligodendrocyte glycoprotein; MS: Multiple sclerosis; PMA: Phorbol
12-myristate 13-acetate; s.c: Subcutaneous; TCR: T cell receptor; TGF: Transforming
growth factor; Treg: Regulatory T cell
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